Investment Rating - The report initiates coverage on Lin Qingxuan with a "Buy" rating and a target price of HKD 130.88, corresponding to a 2026 adjusted PE of 28x [6][11]. Core Insights - Lin Qingxuan focuses on high-end anti-wrinkle and firming products, pioneering the "oil-based skincare" concept. The brand has a clear positioning and product category mindset, with significant growth potential in its market segment [6][10]. - The company has developed its flagship product, Camellia Oil, into its fifth generation, and its "1+4" product strategy includes a diverse range of products such as lotions, toners, creams, serums, and sunscreens, which are expected to drive future growth [6][8]. - Lin Qingxuan's omnichannel sales network supports steady growth in both online and offline sales, with strong R&D capabilities expected to reinforce its market leadership in niche segments and enable product innovation [6][9]. Financial Projections - Revenue projections for Lin Qingxuan are as follows: - 2024: RMB 1,210 million (+50.27%) - 2025: RMB 2,218 million (+83.34%) - 2026: RMB 3,214 million (+44.91%) - 2027: RMB 4,464 million (+38.91%) [5][11]. - Adjusted net profit forecasts are: - 2024: RMB 200.24 million (+126.37%) - 2025: RMB 385.40 million (+92.47%) - 2026: RMB 589.34 million (+52.92%) - 2027: RMB 821.16 million (+39.33%) [5][11]. - The adjusted net profit margin is expected to be 11.0% in 2023 and 16.6% in 2024, indicating improved operational efficiency [10][24]. Market Dynamics - The "oil-based skincare" market is currently experiencing rapid penetration growth, driven by product innovation, increased brand investment in product education, and a shift in consumer awareness towards skin barrier repair [7][21]. - Lin Qingxuan has established a strong brand identity around the Camellia flower ingredient, which has become synonymous with its product offerings, enhancing consumer recognition and loyalty [8][22]. - The company has a robust offline presence with 554 stores as of the first half of 2025, and it is actively expanding its online sales channels, leveraging live streaming and collaborations with KOLs to capture growth opportunities [9][22]. Competitive Positioning - Lin Qingxuan's ability to incubate successful single products and replicate this success across categories positions it favorably within the high-end skincare market, which is relatively concentrated [10][17]. - The company’s focus on high-quality raw materials and integrated supply chain management is expected to solidify its leadership in niche markets [23][24].

Group 1 - Coty Inc. (COTY.US) experienced a significant decline in after-hours trading, dropping over 13% to a price of $2.74 [1]

Core Viewpoint - Coty Inc. reported mixed financial results for Q2 of fiscal year 2026, leading to a significant drop in stock price by over 13% to $2.74 [1] Financial Performance - Revenue for Q2 was $1.68 billion, slightly exceeding market expectations of $1.66 billion [1] - Adjusted earnings per share (EPS) were $0.14, falling short of analyst expectations of $0.18 [1] - The company anticipates a decline in adjusted EBITDA for Q3 to between $100 million and $110 million, which is below the analyst forecast of $201.6 million [1] Management Changes and Future Outlook - Coty has withdrawn its previous forecasts for EBITDA and free cash flow for fiscal year 2026 [1] - The newly appointed interim CEO, Markus Strobel, emphasized the need for improved discipline and execution to address the company's poor financial performance [1]

一场高规格表彰展现的城市态度 回望2025年，广州民营经济交出了一份亮眼的成绩单：全年增加值近1.4万亿元，同比增长5.2%；全市民营经 济主体突破405万户，占市场主体总量的96%，带动广州市场主体数量跃居全国第二。广大民营企业以实干稳 增长、以创新促转型、以担当惠民生，已成为这座城市高质量发展不可或缺的核心力量。 一次高规格的表彰，传递的是一份坚定的信心；一系列连贯的行动，彰显的是一种长期主义的决心。这次大 会，向社会各界清晰释放了广州对民营经济地位和作用高度认可、坚定不移支持的强烈信号，并激励全市非 公有制经济人士乘势而上，在高质量发展赛道上再创佳绩，与城市同频共振、共生共荣。 这份重视，广州一如既往、掷地有声。从市委常委会的专题部署，到市领导高频次的企业走访调研，广州清 晰表达了：民营经济不是配角，而是推动高质量发展、现代化建设的生力军。 这份支持，更体现为制度化的先行与引领。从"老板"到"优秀建设者"，称谓之变的背后，是对民营企业家社 会身份的重新定义和价值贡献的认同。广州也将这种态度，转化为一系列开创性的制度设计： 2月6日，广州市非公有制经济人士优秀中国特色社会主义事业建设者暨光彩事业贡献奖表彰 ...

Group 1 - The core viewpoint of the article highlights that 毛戈平's stock has seen an increase of nearly 3%, currently trading at 92.6 HKD with a transaction volume of 59.54 million HKD [1] - On February 5, 毛戈平 announced that it received approval from the Hong Kong Stock Exchange to list and trade 228 million H-shares, which are the maximum number of unlisted shares to be converted and listed [1] - Goldman Sachs' research indicates that despite challenges in the overall cosmetics industry, 毛戈平 is expected to outperform the market, with projected compound annual growth rates (CAGR) for sales and net profit reaching 23% and 22% respectively from 2025 to 2027 [1] Group 2 - Shenwan Hongyuan forecasts that 毛戈平's gross merchandise volume (GMV) on Douyin is expected to grow by around 50% in 2025, with both skincare and makeup segments contributing to this growth [1] - The profit growth rate for the company is anticipated to be 35% in 2025, indicating strong performance in the upcoming years [1]

Group 1 - The core viewpoint of the article highlights that Mao Geping (01318) has seen a stock price increase of nearly 3%, currently trading at 92.6 HKD with a transaction volume of 59.55 million HKD [1] - On February 5, the company announced that it received approval from the Hong Kong Stock Exchange to list and trade 228 million H-shares, which are the maximum number of unlisted shares convertible and to be listed [1] - Goldman Sachs' research indicates that despite challenges in the overall cosmetics industry, Mao Geping is expected to outperform the market, with projected compound annual growth rates (CAGR) for sales and net profit reaching 23% and 22% respectively from 2025 to 2027 [1] Group 2 - Shenwan Hongyuan forecasts that the company's GMV on Douyin is expected to grow by around 50% in 2025, with both skincare and makeup segments contributing to this growth [1] - The profit growth rate is anticipated to be 35% in 2025, indicating strong performance in the company's financial outlook [1]

Core Viewpoint - Since the beginning of the 14th Five-Year Plan, Shaanxi's drug regulatory system has effectively implemented reforms in drug safety risk prevention and control, aiming for comprehensive regulation of drugs, vaccines, medical devices, and cosmetics by the end of 2025 [1][2] Group 1: Regulatory Reforms - The Shaanxi drug regulatory system has established an integrated operational mechanism to enhance regulatory capabilities, ensuring clear functions and smooth operations of regulatory agencies [1] - The implementation of party and government responsibilities in drug regulation has been effectively carried out, with a well-established food and drug safety committee mechanism at provincial, municipal, and county levels [1] Group 2: Support for Industry Development - Continuous reforms in the review and approval system have supported the high-quality development of the "two products and one device" (drugs, cosmetics, medical devices) industry [1] - The approval of the first Class I innovative drug, Mesylate Prefofovir Tablets, marks a breakthrough for Shaanxi in Class I innovative drugs [1] - Five Class III innovative medical devices have been approved for market entry, and two new cosmetic raw materials have been filed with the National Medical Products Administration [1] - A total of 196 drug varieties have passed or been deemed to have passed the consistency evaluation of generic drugs [1] Group 3: Smart Regulation Initiatives - Shaanxi has established a comprehensive drug regulatory business system and a vaccine (drug) traceability regulatory system, achieving a "one network" operation for drug and device regulation across provincial, municipal, and county levels [2] - Key drugs such as vaccines, special drugs, blood products, and selected products from centralized procurement have achieved full-chain traceability [2] - The integration and sharing of various regulatory information have enabled closed-loop management for risk identification, warning, and response [2]

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial application, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor of NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can quickly elevate NAD levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4]. NAD+ Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse reactions [6][7]. Natural Sources of NMN - Natural food sources of NMN are limited, with NMN supplements providing approximately 300 times the intake efficiency compared to dietary sources [8]. NMN Synthesis Technology - The synthesis of NMN has transitioned from chemical methods to fully enzymatic methods, focusing on high purity, safety, and environmental sustainability [10][11]. - Leading companies are innovating in full enzymatic synthesis technology, establishing competitive advantages through patent applications [12]. Industry Development Drivers: Policy - The regulatory environment for NMN is evolving, with significant progress in China towards legalization as a health food, following the approval of NMN as a cosmetic ingredient [17][18]. Industry Development Drivers: Demand - The aging population and increasing anti-aging awareness among younger generations are driving demand for NMN products, creating a substantial market opportunity [19]. Industry Development Drivers: Technology - Innovations in synthesis, quality testing, and delivery methods are driving the NMN industry towards scale, standardization, and efficiency [21][22]. Application Areas of NMN - NMN is primarily used in health supplements and cosmetics, with potential expansion into pet nutrition, medical health, and agricultural technology [24][28]. Market Size and Growth - The NMN market in China is expected to exceed 3 billion yuan by 2025, driven by policy relaxation and new applications in various sectors [28]. Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60%-70% of market share [35]. Certification System - The "blue hat" certification for health foods represents the highest standard in the NMN industry in China, indicating product safety and compliance [37]. Challenges Facing the NMN Industry - Despite positive regulatory signals, the industry faces challenges such as exaggerated claims, lack of consumer awareness, and the need for technological advancements [61][63].

Core Viewpoint - The Hong Kong stock market is experiencing a divergence in performance, with consumer and dividend sectors showing resilience amidst overall market volatility, while the Hang Seng Technology Index has seen significant declines [1][2]. Market Performance - On February 5, the Hang Seng Index closed at 26,885.24 points, up 0.14%, while the Hang Seng Technology Index rose 0.74% to 5,406.13 points [2]. - The market has been in a state of adjustment, particularly highlighted by a 3.36% drop in the Hang Seng Technology Index on February 2, which reached levels not seen since July 2025 [2]. Factors Influencing Market Trends - The recent market adjustments are primarily attributed to concerns over the Federal Reserve's policy shifts, particularly the proposed combination of "rate cuts + balance sheet reduction" by the newly nominated chair [2]. - Despite the volatility, southbound capital has shown a net inflow for two consecutive trading days, totaling over 38 billion HKD, with nearly 25 billion HKD net bought on February 5, marking the highest single-day net purchase this year [2]. Sector Performance - The consumer sector has seen significant gains, with stocks like Yum China rising over 11%, Miniso up over 6%, and Mao Geping increasing over 5%, leading to strong performance in consumer-themed ETFs [3]. - Approximately 80% of the top fifteen ETFs in terms of growth are focused on the Hong Kong consumer sector, indicating a strong interest in this area despite overall market declines [3]. Investment Outlook - Multiple public fund institutions believe that short-term fluctuations will not alter the long-term positive trend for the Hong Kong market, which remains attractive in terms of value [4]. - The current low valuation levels in the Hong Kong market are expected to provide a buffer against external volatility and make the market more sensitive to potential growth recovery and policy signals [4]. Sector-Specific Insights - The technology sector is anticipated to undergo valuation recovery, driven by technological breakthroughs, continuous inflow of southbound capital, and the Hong Kong market's status as a valuation low point [5][6].

Market Overview - On February 5, the Hong Kong stock market showed a divergence, with major indices rebounding in the afternoon and closing in the green. The Hang Seng Index closed at 26,885.24 points, up 0.14%, while the Hang Seng Tech Index rose 0.74% to 5,406.13 points [2] - The recent market trend has been characterized by volatility, particularly following a significant drop on February 2, when the Hang Seng Tech Index fell by 3.36% [2] Sector Performance - The consumer and dividend sectors demonstrated resilience amidst the overall market turbulence, with several consumer stocks experiencing substantial gains. Notably, Yum China surged over 11%, Miniso increased by over 6%, and Mao Geping rose by over 5% [3] - In the ETF market, consumer-themed ETFs outperformed, with a significant portion of the top-performing ETFs being focused on the consumer sector. On February 4, 70% of the top 20 cross-border ETFs were directed towards Hong Kong dividend themes [3] Investment Outlook - Multiple public fund institutions believe that the short-term volatility will not alter the mid-to-long-term positive trend for the Hong Kong stock market, which remains attractive in terms of valuation. They emphasize the importance of structural investment opportunities [4] - The manager of a mixed fund focused on Hong Kong stocks noted that the market's valuation attractiveness is gradually becoming evident, and there is potential for upward movement despite current fluctuations. Key factors influencing market pricing include corporate earnings and liquidity [4][5] - The outlook for 2026 suggests that improvements in price levels may be a critical variable for market direction, with the appreciation of the Renminbi potentially enhancing liquidity conditions [5]